Karpas Strategies’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | $3.55M | Buy |
127,003
+4
| +0% | +$110 | 1.11% | 26 |
|
|
2024
Q1 | $3.52M | Sell |
126,999
-11,667
| -8% | -$324K | 1.1% | 25 |
|
|
2023
Q4 | $3.99M | Sell |
138,666
-2,334
| -2% | -$70.6K | 1.32% | 21 |
|
|
2023
Q3 | $4.68M | Sell |
141,000
-296
| -0.2% | -$10.5K | 1.72% | 17 |
|
|
2023
Q2 | $5.18M | Buy |
141,296
+691
| +0.5% | +$26.9K | 1.75% | 14 |
|
|
2023
Q1 | $5.74M | Sell |
140,605
-130
| -0.1% | -$5.62K | 2.02% | 12 |
|
|
2022
Q4 | $7.21M | Buy |
140,735
+648
| +0.5% | +$31.1K | 2.53% | 10 |
|
|
2022
Q3 | $6.13M | Buy |
140,087
+702
| +0.5% | +$34.1K | 2.33% | 11 |
|
|
2022
Q2 | $7.31M | Buy |
139,385
+660
| +0.5% | +$33.6K | 2.56% | 11 |
|
|
2022
Q1 | $7.18M | Buy |
138,725
+1,774
| +1% | +$92K | 2.26% | 12 |
|
|
2021
Q4 | $8.09M | Buy |
136,951
+11,503
| +9% | +$570K | 2.59% | 11 |
|
|
2021
Q3 | $5.7M | Hold |
125,448
| – | – | 1.88% | 14 |
|
|
2021
Q2 | $4.91M | Buy |
125,448
+2,271
| +2% | +$88.3K | 1.74% | 16 |
|
|
2021
Q1 | $4.46M | Buy |
123,177
+17,975
| +17% | +$638K | 1.69% | 16 |
|
|
2020
Q4 | $3.87M | Sell |
105,202
-5,681
| -5% | -$208K | 1.52% | 18 |
|
|
2020
Q3 | $3.86M | Hold |
110,883
| – | – | 1.78% | 17 |
|
|
2020
Q2 | $3.44M | Hold |
110,883
| – | – | 1.66% | 18 |
|
|
2020
Q1 | $3.43M | Hold |
110,883
| – | – | 1.86% | 17 |
|
|
2019
Q4 | $4.12M | Hold |
110,883
| – | – | 1.55% | 20 |
|
|
2019
Q3 | $3.78M | Hold |
110,883
| – | – | 1.53% | 21 |
|
|
2019
Q2 | $4.56M | Hold |
110,883
| – | – | 1.89% | 18 |
|
|
2019
Q1 | $4.47M | Sell |
110,883
-568
| -0.5% | -$22.7K | 1.89% | 17 |
|
|
2018
Q4 | $4.62M | Hold |
111,451
| – | – | 2.16% | 12 |
|
|
2018
Q3 | $4.66M | Hold |
111,451
| – | – | 1.92% | 15 |
|
|
2018
Q2 | $3.84M | Sell |
111,451
-3,215
| -3% | -$110K | 1.66% | 16 |
|
|
2018
Q1 | $3.86M | Sell |
114,666
-1,792
| -2% | -$61.6K | 1.68% | 19 |
|
|
2017
Q4 | $4M | Hold |
116,458
| – | – | 1.72% | 17 |
|
|
2017
Q3 | $3.94M | Hold |
116,458
| – | – | 1.73% | 18 |
|
|
2017
Q2 | $3.71M | Hold |
116,458
| – | – | 1.67% | 20 |
|
|
2017
Q1 | $3.78M | Buy |
116,458
+422
| +0.4% | +$13.3K | 1.73% | 20 |
|
|
2016
Q4 | $3.58M | Sell |
116,036
-422
| -0.4% | -$12.9K | 1.69% | 20 |
|
|
2016
Q3 | $3.74M | Hold |
116,458
| – | – | 1.83% | 17 |
|
|
2016
Q2 | $3.89M | Buy |
116,458
+106
| +0.1% | +$3.38K | 1.94% | 15 |
|
|
2016
Q1 | $3.27M | Hold |
116,352
| – | – | 1.7% | 18 |
|
|
2015
Q4 | $3.56M | Sell |
116,352
-2,635
| -2% | -$82.9K | 1.88% | 17 |
|
|
2015
Q3 | $3.55M | Hold |
118,987
| – | – | 1.96% | 15 |
|
|
2015
Q2 | $3.79M | Sell |
118,987
-158
| -0.1% | -$5.15K | 1.89% | 15 |
|
|
2015
Q1 | $3.93M | Sell |
119,145
-2,846
| -2% | -$90.5K | 1.91% | 15 |
|
|
2014
Q4 | $3.6M | Hold |
121,991
| – | – | 1.73% | 19 |
|
|
2014
Q3 | $3.42M | Buy |
121,991
+27,299
| +29% | +$766K | 1.71% | 19 |
|
|
2014
Q2 | $2.67M | Buy |
94,692
+421
| +0.4% | +$12K | 1.33% | 26 |
|
|
2014
Q1 | $2.87M | Sell |
94,271
-790
| -0.8% | -$23.6K | 1.53% | 23 |
|
|
2013
Q4 | $2.76M | Sell |
95,061
-633
| -0.7% | -$18.4K | 1.52% | 25 |
|
|
2013
Q3 | $2.61M | Hold |
95,694
| – | – | 1.53% | 25 |
|
|
2013
Q2 | $2.54M | Buy |
+95,694
| New | +$2.64M | 1.56% | 24 |
|
Other funds holding PFE
Karpas Strategies's PFE Position: Q2 2024 in Review
Karpas Strategies increased its Pfizer (PFE) stake by 0% in Q2 2024, buying an estimated $110 and bringing the position to 127,003 shares worth $3.55M. The position accounts for 1.11% of the portfolio, ranked #26.
Karpas Strategies first reported a position in PFE in Q2 2013 and has held it in 45 quarters since. The position peaked at $8.09M in Q4 2021. 2,874 funds tracked by Wall St. Rank hold PFE as of Q2 2024.
- Karpas Strategies held 127,003 shares of Pfizer worth $3.55M as of Q2 2024.
- Karpas Strategies bought 4 Pfizer shares in Q2 2024, an estimated $110.
- Pfizer made up 1.11% of Karpas Strategies's portfolio in Q2 2024, its #26 holding.
- Karpas Strategies first reported a position in Pfizer in Q2 2013 and has held it in 45 quarters since.
- Karpas Strategies's Pfizer position peaked at $8.09M in Q4 2021.
- 2,874 funds tracked by Wall St. Rank held Pfizer as of Q2 2024.
Based on Karpas Strategies's 13F filing for Q2 2024, filed 30 Jul 2024.